利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.012 秒)

    OLEDS CONTAINING THERMALLY STABLE ASYMMETRIC CHARGE CARRIER MATERIALS
    3.
    发明申请
    OLEDS CONTAINING THERMALLY STABLE ASYMMETRIC CHARGE CARRIER MATERIALS 审中-公开
    包含热稳定不对称充电载体材料的OLEDs

    公开(公告)号：WO99013691A1

    公开(公告)日：1999-03-18

    申请号：PCT/US1998/018363

    申请日：1998-09-04

    IPC分类号： C07C211/54 ,  C07C211/58 ,  H01L51/50 ,  H05B33/12 ,  C07C211/00 ,  C07C211/33 ,  C07C211/43

    CPC分类号： C07C211/54 ,  C07C211/58 ,  H01L51/0059 ,  H01L51/006 ,  H01L51/0071 ,  H01L51/5012 ,  Y10S428/917 ,  Y10T428/31504

    摘要： Organic light emitting devices are disclosed which are comprised of an organic charge carrier layer formed from a charge carrier material that is capable of forming a stable glass due to the presence of a compound having an asymmetric molecular structure in the charge carrier material. For example, the OLED may contain hole transporting layers comprised of compounds having an asymmetric molecular structure in which hole transporting substituents are asymmetrically located around a core atom or core chemical group. The core atom may be a nitrogen atom or the core chemical group may be comprised of a single phenylene group or a biphenylene group which is substituted with at least two hole transporting amine groups, wherein at least one of the amine groups is different from at least one other amine group. For example, the compound may have the asymmetric molecular structure as shown by formula (I), wherein R1, R2, R3, R4, R5 and R6 are, independently of one another, hole transporting amine groups, or hydrogen, with the proviso that at least two amine groups are present and at least one of the amine groups is different from at least one other amine group. Typically, R1 and R4 are hole transporting amine groups wherein R1 is different from R4.

    摘要翻译： 公开了有机发光器件，其由由能够形成稳定玻璃的电荷载体材料形成的有机电荷载体层组成，这是由于在电荷载体材料中存在具有不对称分子结构的化合物。 例如，OLED可以包含由不对称分子结构的化合物构成的空穴传输层，其中空穴传输取代基不对称地位于核心原子或核心化学基团周围。 核心原子可以是氮原子，或者核心化学基团可以由被至少两个空穴传输胺基取代的单个亚苯基或亚联苯基组成，其中至少一个胺基至少不同于 另一个胺基团。 例如，化合物可以具有如式（I）所示的不对称分子结构，其中R 1，R 2，R 3，R 4，R 5和R 6彼此独立地为空穴传输胺基或氢，条件是 存在至少两个胺基，并且至少一个胺基不同于至少一个其它胺基。 通常，R 1和R 4是空穴传输胺基，其中R 1不同于R 4。

    OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME
    8.
    发明申请
    OXADIAZOLE AMINE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME 审中-公开
    恶二唑胺衍生物化合物作为组蛋白脱乙酰酶6的抑制剂，以及包含该组合物的药物组合物

    公开(公告)号：WO2017065473A1

    公开(公告)日：2017-04-20

    申请号：PCT/KR2016/011355

    申请日：2016-10-11

    申请人： CHONG KUN DANG PHARMACEUTICAL CORP.

    发明人： KIM, Yuntae ,  LEE, Chang Sik ,  OH, Jung Taek ,  SONG, Hyeseung ,  CHOI, Jin ,  LEE, Jaeyoung

    IPC分类号： C07D413/04 ,  C07D271/10 ,  C07D271/06 ,  C07C211/33 ,  C07C211/35 ,  A61K31/4245 ,  A61K31/506

    CPC分类号： C07D271/10 ,  C07D413/04 ,  C07D413/14

    摘要： The present disclosure relates to novel compounds having histone deacetylase 6 (HDAC6) inhibitory activity, stereoisomers thereof or pharmaceutically acceptable salts thereof, the use thereof for the preparation of therapeutic medicaments, pharmaceutical compositions containing the same, a method for treating diseases using the composition, and methods for preparing the novel compounds. The novel compounds, stereoisomers thereof or pharmaceutically acceptable salts thereof according to the present disclosure have histone deacetylase (HDAC) inhibitory activity and are effective for the prevention or treatment of HDAC6-mediated diseases, including infectious diseases; neoplasms; endocrine, nutritional and metabolic diseases; mental and behavioral disorders; neurological diseases; diseases of the eye and adnexa; cardiovascular diseases; respiratory diseases; digestive diseases; diseases of the skin and subcutaneous tissue; diseases of the musculoskeletal system and connective tissue; or congenital malformations, deformations and chromosomal abnormalities.

    摘要翻译： 本发明涉及具有组蛋白脱乙酰酶6（HDAC6）抑制活性的新化合物，其立体异构体或其药学上可接受的盐，其在制备治疗药物中的用途，含有其的药物组合物， 使用该组合物治疗疾病的方法，以及制备该新化合物的方法。 本发明的新化合物，其立体异构体或其药学上可接受的盐具有组蛋白脱乙酰酶（HDAC）抑制活性，并且可有效预防或治疗HDAC6介导的疾病，包括感染性疾病; 肿瘤; 内分泌，营养和代谢疾病; 精神和行为障碍; 神经疾病; 眼睛和附属器疾病; 心血管疾病; 呼吸疾病; 消化系统疾病; 皮肤和皮下组织疾病; 肌肉骨骼系统和结缔组织疾病; 或先天性畸形，畸形和染色体异常。